tbuckley/cabot-search huggingface dataset:
Issue Information
Authors: C Venter, R Frei, G Spolidoro, Y Amera, M Ali, S Nyassi, D Lisik, A Ioannidou, G Rovner, E Khaleva, R Van Ree, M Worm, B Vlieg-Boerstra, A Sheikh, A Muraro, G Roberts, B Nwaru, H.-P Zhang, Y.-L Sun, Y.-F Wang, D Yazici, D Azkur, I Ogulur, A Azkur, Z.-W Yang, X.-X Chen, A.-Z Zhang, J.-Q Hu, G.-H Liu, M Akdis, C Akdis, Y.-D Gao, A Kaplan, M Lebwohl, A Giménez-Arnau, M Hide, A Armstrong, M Maurer, G Gauvreau, C Bergeron, L.-P Boulet, D Cockcroft, A Côté, B Davis, R Leigh, I Myers, P O'byrne, R Sehmi, K Lee-Sarwar, Y.-C Chen, A Kozyrskyj, P Mandhane, S Turvey, P Subbarao, H Bisgaard, J Stokholm, B Chawes, S Sørensen, R Kelly, J Lasky-Su, R Zeiger, G O'connor, M Sandel, L Bacharier, A Beigelman, V Carey, B Harshfield, N Laranjo, D Gold, S Weiss, A Litonjua, G Gürdeniz, M Kim, N Brustad, M Ernst, F Russo, K Bønnelykke, D Hougaard, M Rasmussen, A Cohen, B Zhang, L Roesner, S Traidl, V Koeken, C.-J Xu, T Werfel, Y Li, T Kauppila, V Hinkkanen, T Savinko, P Karisola, A Kukkonen, M Paassilta, A Pelkonen, M Mäkelä, S Avlas, G Shani, N Rhone, M Itan, A Dolitzky, I Hazut, S Grisaru-Tal, Y Gordon, T Shoda, A Ballaban, N Ben-Baruch, M Rochman, Y Diesendruck, L Nahary, A Bitton, Z Halpern, I Benhar, C Varol, M Rothenberg, A Munitz, A Binder, D Cherry-Brown, B Biggerstaff, E Jones, C Amelio, C Beard, L Petersen, G Kersh, S Commins, P Armstrong, S Tedner, S Klevebro, A Bergström, I Kull, N Andersson, M Borres, N Ballardini, M Westman, J Konradsen, M Van Hage, C Nilsson, E Melén, A Asarnoj, L Hung, A Celik, X Yin, K Yu, A Berenjy, A Kothari, H Obernolte, J Upton, K Lindholm Bøgh, G Somers, I Siddiqui, M Grealish, F Quereshy, K Sewald, P Chiu, T Eiwegger, X Jia, S Bunyavanich, P Brennan, T Hanif, L Ivaska, F Ahmad, G Tan, E Mikola, T Puhakka, O Palomares, S Toppila-Salmi, T Jartti, T Matsui, H Yamashita, K Kitamura, A Makino, Y Takasato, S Sugiura, K Ito, Fcεri -Activated Basophils Express Ccr4, Xcr1 Blom, E Bartko, T Møller, L Poulsen, B Jensen, Z Fneish, J Becker, F Mulenge, B Costa, L Krajewski, V Duran, A Ziegler, V Sommer, C Traidl-Hoffmann, S Gilles, U Kalinke, R Murphy, Y.-H Chow, Y Lai, T Al-Shaikhly, D Petroni, M Black, J Hamerman, A Lacy-Hulbert, A Piliponsky, T Hallstrand, S Dramburg, S Perna, M Di Fraia, S Tripodi, S Arasi, S Castelli, D Villalta, F Buzzulini, I Sfika, V Villella, E Potapova, M Brighetti, A Travaglini, S Pelosi, U Grittner, P Matricardi, L Mastalerz, R Kacorzyk, B Jakieła, A Ćmiel, M Sanak, A Koskinen, R Lemmetyinen, A Luukkainen, H Kankaanranta, P Ilmarinen, J Karjalainen, J Pekkanen, H Huhtala, J Haukka, A But, L Ravanetti, T Dekker, L Guo, A Dijkhuis, B Dierdorp, Z Diamant, S Florquin, R Lutter, M Gotoh, T Kurokawa, S Yonekura, M Okano, Y Maekawa, Y Okamoto, K Okubo, I Mogensen, C Flodström, A Nopp, B Ungar, S Hartzell, D Lozano-Ojalvo, S Ghalili, S Bose, A Golant, K Tan, Y Estrada, G Singer, A Pavel, P Cravedi, E Guttman-Yassky
Journal: Allergy (2023)
Ensuring equitable access to guideline-based asthma care across the lifespan: Tips and future directions to the successful implementation of the new NAEPP 2020 guidelines, a Work Group Report of the AAAAI Asthma, Cough, Diagnosis, and Treatment Committee
Authors: Anil Nanda, Roxana Siles, Henna Park, Margee Louisias, Barbara Ariue, Maria Castillo, Mahesh Padukudru Anand, Anh P. Nguyen, Tiffany Jean, Michael Lopez, Roula Altisheh, Andrea A. Pappalardo
Journal: Journal of Allergy and Clinical Immunology (2023)
Insights on drug and gene delivery systems in liver fibrosis
Authors: Kunj Vyas, Mayur M Patel
Journal: Asian Journal of Pharmaceutical Sciences (2023)

Complications of the liver are amongst the world's worst diseases. Liver fibrosis is the first stage of liver problems, while cirrhosis is the last stage, which can lead to death. The creation of effective anti-fibrotic drug delivery methods appears critical due to the liver's metabolic capacity for drugs and the presence of insurmountable physiological impediments in the way of targeting. Recent breakthroughs in anti-fibrotic agents have substantially assisted in fibrosis; nevertheless, the working mechanism of anti-fibrotic medications is not fully understood, and there is a need to design delivery systems that are well-understood and can aid in cirrhosis. Nanotechnology-based delivery systems are regarded to be effective but they have not been adequately researched for liver delivery. As a result, the capability of nanoparticles in hepatic delivery was explored. Another approach is targeted drug delivery, which can considerably improve efficacy if delivery systems are designed to target hepatic stellate cells (HSCs). We have addressed numerous delivery strategies that target HSCs, which can eventually aid in fibrosis. Recently genetics have proved to be useful, and methods for delivering genetic material to the target place have also been investigated where different techniques are depicted. To summarize, this review paper sheds light on the most recent breakthroughs in drug and gene-based nano and targeted delivery systems that have lately shown useful for the treatment of liver fibrosis and cirrhosis.
The E3 ubiquitin ligase NEDD4-1 protects against acetaminophen-induced liver injury by targeting VDAC1 for degradation
Authors: Yiwei Zhu, Lin Lei, Xinghui Wang, Linfang Chen, Wei Li, Jinxia Li, Chenchen Zhao, Xiliang Du, Yuxiang Song, Wenwen Gao, Guowen Liu, Xinwei Li
Journal: Acta Pharmaceutica Sinica B (2023)

Acetaminophen (APAP) overdose is a major cause of liver injury. Neural precursor cell expressed developmentally downregulated 4-1 (NEDD4-1) is an E3 ubiquitin ligase that has been implicated in the pathogenesis of numerous liver diseases; however, its role in APAP-induced liver injury (AILI) is unclear. Thus, this study aimed to investigate the role of NEDD4-1 in the pathogenesis of AILI. We found that NEDD4-1 was dramatically downregulated in response to APAP treatment in mouse livers and isolated mouse hepatocytes. Hepatocyte-specific NEDD4-1 knockout exacerbated APAP-induced mitochondrial damage and the resultant hepatocyte necrosis and liver injury, while hepatocyte-specific NEDD4-1 overexpression mitigated these pathological events both in vivo and in vitro. Additionally, hepatocyte NEDD4-1 deficiency led to marked accumulation of voltage-dependent anion channel 1 (VDAC1) and increased VDAC1 oligomerization. Furthermore, VDAC1 knockdown alleviated AILI and weakened the exacerbation of AILI caused by hepatocyte NEDD4-1 deficiency. Mechanistically, NEDD4-1 was found to interact with the PPTY motif of VDAC1 through its WW domain and regulate K48-linked ubiquitination and degradation of VDAC1. Our present study indicates that NEDD4-1 is a suppressor of AILI and functions by regulating the degradation of VDAC1.
Urinary Phenazopyridine Stones
Authors: William P. Mulvaney
Journal: JAMA (1972)

Phenazopyridine hydrochloride (Pyridium) is an analgesic used in the urinary tract. Vesical calculi have been removed composed of almost pure phenazopyridine. The calculi were analyzed by x-ray diffraction, spectroscopy, and chemical quantitation. Large and prolonged dosage combined with urinary concentration may have caused the calculus growth. This case demonstrates the importance of crystallographic analysis of urinary tract calculi.
Extending Cystoscopic Techniques Into the Ureter and Renal Pelvis
Authors: Jeffry L. Huffman
Journal: JAMA (1983)

The availability of extended-length, small-caliber endoscopes allows the use of many cystoscopic techniques in the ureter and renal pelvis. Although the instruments are rigid, they can be passed transurethrally in both male and female patients to allow the urologist to diagnose and treat many lesions of the upper urinary tract. The success of our series demonstrates the utility and safety of the technique, which often eliminates the need for surgical exposure of the lesions. (<i>JAMA</i>1983;250:2002-2005)
A Controlled Trial of Tacrine in Alzheimer's Disease
Authors: Martin Farlow
Journal: JAMA (1992)

<h3>Objective.</h3> —To compare efficacy and safety of tacrine hydrochloride with placebo in patients with probable Alzheimer's disease. <h3>Design.</h3> —A 12-week, double-blind, placebo-controlled, parallel-group study. <h3>Setting.</h3> —Outpatients at 23 centers. <h3>Patients.</h3> —Men and women with probable Alzheimer's disease, at least 50 years old, mildly to moderately impaired, without other significant medical conditions. <h3>Interventions.</h3> —In the initial 6 weeks, patients received placebo, 20 mg/d of tacrine, or 40 mg/d of tacrine. In the second 6 weeks, half received the same treatment and half increased tacrine dose: those receiving placebo increased to 20 mg/d, those receiving 20 mg/d increased to 40 mg/d, and those receiving 40 mg/d increased to 80 mg/d. <h3>Primary Outcome Measures.</h3> —Alzheimer's Disease Assessment Scale (ADAS) cognitive component and clinician-rated Clinical Global Impression of Change (CGIC). <h3>Results.</h3> —Four hundred sixty-eight patients entered. After 12 weeks, dose-related improvement was significant on the ADAS cognitive (<i>P</i>=.014), clinician-rated CGIC (<i>P</i>=.014), and caregiver-rated CGIC (<i>P</i>=.006). Comparison of 80 mg/d with placebo showed significant improvement on the ADAS cognitive (<i>P</i>=.015), clinician-rated CGIC (<i>P</i>=.016), and caregiver-rated CGIC (<i>P</i>=.028). Significant effects appeared as early as 6 weeks on the ADAS cognitive and caregiver-rated CGIC. Among patients receiving 80 mg/d of tacrine, 51% achieved a four-point or greater improvement of the ADAS cognitive component after 12 weeks of treatment. Reversible asymptomatic transaminase elevations greater than three times normal occurred in 25% of patients. Other treatment-related events included nausea and/or vomiting (8%), diarrhea (5%), abdominal pain (4%), dyspepsia (3%), and rash (3%). <h3>Conclusions.</h3> —These results confirm the efficacy and safety of tacrine in some patients with Alzheimer's disease. After 12 weeks, the magnitude of the treatment effect is clinically important and recognized by the physician and caregiver. Liver toxicity is reversible and easily detected by weekly alanine aminotransferase determinations. (<i>JAMA</i>. 1992;268:2523-2529)
The American Health Care System
Authors: John K. Iglehart
Journal: New England Journal of Medicine (1992)

Six times in the 20th century, America has flirted unsuccessfully with national health insurance legislation — the provision of medical care to all citizens. Instead, policy makers have allowed subsidies to finance part of private health insurance by exempting employer-paid premiums from taxation. The government has also provided or funded services for groups deemed particularly vulnerable or entitled to them —Native Americans, migratory workers, other categorically defined poor people, veterans of military service, the permanently disabled, people with end-stage renal disease, and all elderly people. Medicare, which provides the nation's elderly with ready access to short-term medical services, represents the . . .
Hormone Therapy for the Prevention of Chronic Conditions in Postmenopausal Women: Recommendations from the U.S. Preventive Services Task Force
Journal: Annals of Internal Medicine (2005)

This statement summarizes the U.S. Preventive Services Task Force recommendations on hormone therapy for the prevention of chronic conditions in postmenopausal women and the supporting scientific evidence, and updates the Task Force's 2002 recommendations on hormone replacement therapy. The updated statement is based on the results of the Women's Health Initiative randomized, controlled trial, as well as the information in the 2002 summary of the evidence on this topic, which is available on the USPSTF Web site (www.preventiveservices.ahrq.gov). *For a list of the members of the U.S. Preventive Services Task Force, see the Appendix.
Screening for Bone Metastases
Authors: David A. Pistenma
Journal: JAMA (1975)

The results of total skeletal scintigraphy with technetium 99m-labeled diphosphonate in 200 patients with biopsy-proven primary cancer demonstrated abnormalities in 114; 57 had normal roentgenograms. In 32 of the 57 patients, the abnormalities were ascribed to malignant lesions. This is a false-negative rate of 17% for the roentgenographic examinations. Only three patients had abnormal roentgenograms but normal scans, a yield of 1.6% false-negative scans. In a comparison of scan and roentgenographic findings with the skeleton divided into 12 regions, 119 of 160 abnormalities seen on scans but not on roentgenograms were attributed to tumor. Only five of 17 regions that were abnormal on roentgenogram but not on scans were unexplained false-negative findings. Thus, on a regional basis, the yields of false-negative roentgenograms and scans were 9.1% and 0.4%, respectively. (<i>JAMA</i>231:46-50, 1975)
Phase I and Pharmacokinetic Study of the Dolastatin 10 Analogue TZT-1027, Given on Days 1 and 8 of a 3-Week Cycle in Patients with Advanced Solid Tumors
Authors: Maja J.A. de Jonge, Ate van der Gaast, André S.T. Planting, Leny van Doorn, Aletta Lems, Inge Boot, Jantien Wanders, Masahiko Satomi, Jaap Verweij
Journal: Clinical Cancer Research (2005)

Abstract Purpose: TZT-1027 {N2-(N,N-dimethyl-l-valyl)-N-[(1S,2R)-2-methoxy-4-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)]amino]propyl]-1-pyrrolidinyl]-1-[(S)-1-methylpropyl]-4-oxobutyl]-N-methyl-l-valinamide} is a cytotoxic dolastatin 10 derivative inhibiting microtubule assembly through the binding to tubulins. The objectives of this phase I study was to assess the dose-limiting toxicities (DLT), to determine the maximum tolerated dose, and to study the pharmacokinetics of TZT-1027 when given i.v. over 60 minutes on days 1 and 8 every 3 weeks to patients with advanced solid tumors. Experimental Design: Patients were treated with escalating doses of TZT-1027 at doses ranging from 1.35 to 2.7 mg/m2. For pharmacokinetic analysis, plasma sampling was done during the first and second course and assayed using a validated high-performance liquid chromatographic assay with mass spectrometric detection. Results: Seventeen patients received a total of &amp;gt;70 courses. The stopping dose was reached at 2.7 mg/m2, with neutropenia and infusion arm pain as DLT. Neutropenia was not complicated by fever. Over all dose levels, eight patients experienced pain in the infusion arm 1 to 2 days after administration of the drug, which seemed ameliorated by adding additional flushing after drug administration. Other side effects included nausea, vomiting, diarrhea, and fatigue. One partial response lasting &amp;gt;54 weeks was observed in an extensively pretreated patient with metastatic liposarcoma. The pharmacokinetics of TZT-1027 suggested linearity over the dose ranges. No correlation between body surface area and absolute CL of TZT-1027 was established, vindicating that a flat dosing regimen might be used in the future. A correlation was observed between the percentage decrease in neutrophil count and the AUC of TZT-1027. Conclusions: In this study, the DLT of TZT-1027 was neutropenia and infusion arm pain. The recommended dose for phase II studies of TZT-1027 is 2.4 mg/m2 given i.v. over 60 minutes, on days 1 and 8 every 21 days. Phase II studies have recently started.
Kidney Transplantation
Authors: Kurt H. Stenzel
Journal: JAMA (1974)

A grossly abnormal lower urinary tract has often been considered a contraindication to transplantation. Our studies indicate, however, that excellent results can be achieved with intestinal conduits when the bladder is irreparably damaged. Nine transplants were done in eight patients with intestinal conduits in our series of 300 consecutive transplants (incidence of 3%). Ages ranged from 8 to 45 years and five patients were 14 years of age. Renal failure was caused by lower urinary tract disease in all-cases. Seven donors were related to patients and two were cadaveric. There were two deaths, both unrelated to the conduit. The remaining six patients continue to do well with excellent kidney function one to five years after transplantation. Recurrent renal infection always signified partial ureteral obstruction, for which three patients required ureteral revision one to two years after transplantation. The conduits did not lead to any other complications. (<i>JAMA</i>229:534-537, 1974)
Continuing medical education (Dermatologic surgery)
Authors: Douglas Torre
Journal: Journal of the American Academy of Dermatology (1986)

Cryosurgery is now a widely accepted modality for the treatment of basal cell carcinomas. This article presents a practical approach to using cryosurgery for this purpose in the dermatologist's office. Understanding the cryobiologic basis of cryosurgery is a prerequisite. Aspects of treatment covered include selection and use of appropriate equipment, indications and contraindications for specific tumors, preoperative preparation, various treatment technics with clinical and instrumental depth-dose monitoring, postoperative care, cure rate, and cosmetic and functional end results. The overall results obtained by cryosurgery compare favorably with those obtained by other modalities. Cryosurgery is the treatment of choice for some basal cell carcinomas and a satisfactory alternate treatment for others. Cryosurgery is now a widely accepted modality for the treatment of basal cell carcinomas. This article presents a practical approach to using cryosurgery for this purpose in the dermatologist's office. Understanding the cryobiologic basis of cryosurgery is a prerequisite. Aspects of treatment covered include selection and use of appropriate equipment, indications and contraindications for specific tumors, preoperative preparation, various treatment technics with clinical and instrumental depth-dose monitoring, postoperative care, cure rate, and cosmetic and functional end results. The overall results obtained by cryosurgery compare favorably with those obtained by other modalities. Cryosurgery is the treatment of choice for some basal cell carcinomas and a satisfactory alternate treatment for others.
Immunoblastic Lymphadenopathy
Authors: Jesse I. Spector
Journal: JAMA (1977)

Two patients with immunoblastic lymphadenopathy had lymphadenopathy, hepatosplenomegaly, rash, dysproteinemia, constitutional symptoms, and typical morphologic findings of lymph node obliteration by immunoblasts and plasma cells, proliferation of arborizing vessels, and infiltration with amorphous, eosinophilic material. One patient had massive pulmonary infiltrates that responded to steroid therapy early in the course of the disease, but recurred and were found, at autopsy, to represent immunoblastic invasion of the lung. In both cases, a severe peripheral neuropathy developed during the course of the disease. One patient was addicted to dextroamphetamine for 20 years. Response to corticosteroids and cytotoxic therapy was initially rapid and complete, but refractoriness developed as seen in postmortem findings of extensive visceral involvement. (<i>JAMA</i>238:1263-1265, 1977)
Monarthric Arthritis Caused by Metastatic Breast Carcinoma
Authors: Haralampos M. Moutsopoulos
Journal: JAMA (1975)

ALTHOUGH breast carcinoma commonly metastasizes to bone, involvement of the knee is unusual. In his review of metastatic bone disease in patients with breast cancer, Galasko<sup>1</sup>mentioned no such instance. We report a patient with widespread mammary carcinoma in whom metastatic cancer of the knee was diagnosed by cytologic examination of the synovial fluid. <h3>Report of a Case</h3> In 1962, a woman, then 44 years old, underwent right radical mastectomy with postoperative irradiation for infiltrating ductal carcinoma with metastases to local lymph nodes. She was free of symptoms for five years. In 1967, chest pain, cough, and hemoptysis led to roentgenographic observation of a solitary coin lesion in the right lower lobe of the lung. The lesion regressed in response to estrogen therapy. In 1971, she felt persistent pain in the left knee. Roentgenographic bone survey and radioisotope bone scan showed no abnormality, and the knee showed only minimal degenerative
Cervical Chlamydia trachomatis and Mycoplasmal Infections in Pregnancy
Authors: H. Robert Harrison
Journal: JAMA (1983)

In a prospective study of chlamydial and mycoplasmal infections in pregnancy,<i>Chlamydia trachomatis</i>occurred in 8.0%,<i>Mycoplasma hominis</i>in 23.5%, and<i>Ureaplasma urealyticum</i>in 72.3% of 1,365 enrollees. By multivariate analysis,<i>C trachomatis</i>was correlated with lower socioeconomic status, age 23 years or younger, and 12 years or less of schooling.<i>Ureaplasma urealyticum</i>was correlated with age 23 years or younger and lower socioeconomic status.<i>Mycoplasma hominis</i>was correlated with more than one recent sexual partner, first intercourse at age 17 years or younger, and higher socioeconomic status. These cervical infections did not predict low birth weight, abortion, stillbirth, prematurity, or premature rupture of membranes. Only<i>M hominis</i>predicted endometritis/fever after vaginal delivery (relative risk, 7.3). IgM-seropositive<i>C trachomatis</i>—infected women had more low-birth-weight infants and more premature rupture of membranes than either IgM-negative<i>C trachomatis</i>—infected women or<i>C trachomatis</i>culture-negative women. Thus, only certain subgroups of infected women may experience adverse pregnancy outcomes. (<i>JAMA</i>1983;250:1721-1727)
Neuroleptic-lnduced Akathisia and Dystonia Triggered by Alcohol
Authors: Elmar G. Lutz
Journal: JAMA (1976)

Subclinical extrapyramidal symptoms caused by phenothiazine or butyrophenone derivatives can become manifest during and shortly after the consumption of alcohol. Alcohol appears to lower the threshold of resistance to neurotoxic side effects of previously established neuroleptic drugs. Abstinence from alcohol should be routine advice during neuroleptic psychopharmacotherapy. (<i>JAMA</i>236:2422-2423, 1976)
Clinical effectiveness of active Alpha-Stim AID versus sham Alpha-Stim AID in major depression in primary care in England (Alpha-Stim-D): a multicentre, parallel group, double-blind, randomised controlled trial
Authors: Richard Morriss, Shireen Patel, Clement Boutry, Priya Patel, Boliang Guo, Paul M Briley, Deborah Butler, Michael Craven, Ashley Duncan, Christopher Griffiths, Fred Higton, Rebecca McNaughton, Neil Nixon, Vibhore Prasad, Kapil Sayal, David Smart, Azhar Zafar, Joe Kai
Journal: The Lancet Psychiatry (2023)
Conductive Antifouling Sensing Coating: A Bionic Design Inspired by Natural Cell Membrane
Authors: Yi Huang, Haiping Wu, Ning Xie, Xuewen Zhang, Zhenyang Zou, Meng Deng, Wei Cheng, Xiaolan Guo, Shijia Ding, Bin Guo
Journal: Advanced Healthcare Materials (2023)

Abstract Constructing antifouling coatings for biosensing interfaces is a major hurdle in driving their practical application. Inspired by the excellent antifouling properties of natural cell membranes, a conductive biomimetic antifouling interface coating is proposed, which highly mimics the excellent antifouling properties of biofilms while overcoming the low conductivity defects of conventional coatings. Polyethylene glycol–Au gel is selected as the support structure and electron transfer layer, on which phospholipids and ampholytes are applied to construct a hydration layer for antifouling. The coating maintains promisingly low adsorption in biological matrices such as whole blood, serum, and urine, and has been utilized to construct multimodal clinical assay systems that provide favorable concordance with clinical results. Thus, this conductive bio‐coating breaks the last barrier of biosensors toward practical applications and possesses extremely significant application value.